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Clinical
Abstract
Case presentation
A 79-year-old man was referred with a month’s history of 
being generally unwell with fever, rigors, new confusion and 
weight loss. The patient was a retired economics lecturer, 
lived with his wife and pet dog, maintained independence in 
all activities of daily living and continued to drive. There was 
no history of recent travel.
He had a signifi cant past medical history including: four 
malignancies diagnosed in the last fi ve years. He had had 
a basal cell carcinoma in the context of recurrent scalp 
actinic keratosis, which was removed in March 2018. 
Adenocarcinoma of the lung (T1b N0 M0) and prostate 
(Gleason 4+5, T3a N1 M0) had been treated respectively with 
radical radiotherapy to the lung in May 2015 and radiotherapy 
to the whole pelvis and prostate in September 2016. For the 
latter he also received 18 months of androgen deprivation 
therapy but he did not complete the full course because of 
side effects. There was no evidence of recurrence of cancer 
at either of these two sites since. He had also suffered 
a transient ischaemic attack (TIA) in 2016 and had an 
established history of chronic obstructive pulmonary disease, 
benign retrosternal goitre, recurrent episodes of anxiety and 
depression, glaucoma, recurrent uveitis and deafness.
Following investigation for visible haematuria, he was 
diagnosed with bladder cancer and in October 2017 
underwent trans-urethral resection of bladder tumour (TURBT) 
followed by single instillation of mitomycin. Histology revealed 
high-grade non-muscle invasive urogenital carcinoma (Grade 
3, pT1) and he was offered a standard regimen of 15 Bacillus 
Calmette-Guérin (BCG) instillations starting in January 2018, 
which comprised an induction course of six instillations 
followed by three maintenance courses of three instillations 
with cystoscopic surveillance in between. Cystoscopic 
surveillance revealed no disease recurrence.
After the tenth BCG instillation in September 2018, he 
developed shivers which resolved within four days. Following 
the 11th BCG instillation, one week later, BCG therapy was 
interrupted because the patient developed sustained fever 
and new urinary retention. He was admitted to hospital 
and treated empirically for a urinary tract infection with 
intravenous co-amoxiclav followed by a week’s course of oral 
ciprofl oxacin. Before discharge home he was also trained 
to intermittently self-catheterise to relieve retention in the 
future. Microscopy and culture of urine, submitted after 
therapy had been started, showed no growth. 
A fortnight following discharge, in mid-October 2018, the 
patient continued to suffer fever. At this stage, he was 
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Intra-vesical Bacillus Calmette-Guérin (BCG) immunotherapy is an effective 
treatment for high-risk bladder cancer. Less well known is that fewer than 
1% of patients receiving BCG treatment can develop disseminated BCG. The 
reaction can range from a mild  u-like illness to a systemic disorder with 
a fulminant course which in the most severe cases can lead to death. The 
diagnostic yield is low and diagnosis is often made after a comprehensive 
exclusion of more common causes of pyrexia of unknown origin. A high level of suspicion 
is therefore required in those who may be at risk. We report a case of disseminated BCG in 
an older patient for whom early involvement of his family was pertinent to determining the 
precipitant for delirium.
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Table 1 Investigations undertaken
Investigation Result (laboratory normal range) units
Haematology and biochemistry (admission bloods)
Haemoglobin
White blood cells
Neutrophils
Lymphocytes
Platelets
C-reactive protein
Sodium
Potassium
Urea
Creatinine
Electronic glomerular fi ltration rate (eGFR)
Bilirubin
Alkaline phosphatase 
Alanine aminotransferase
Albumin
Prostate-specifi c antigen
98 (130 – 180) g/l
2.94 (4 – 11) x 109/l 
2.33 (1.8 – 7.5) x 109/l
0.53 (1.0 – 4.0) x 109/l
99 (150 – 400) x109/l
90 (0 – 10) mg/l
127 (133 – 146) mmol/l
3.4 (3.5 – 5.3) mmol/l
7.4 (2.5 – 7.8) mmol/l
77 (64 – 104) umol/l
82 (90 – 500) ml/min/1.73m2
25 (0 -21) umol/l
657 (30 – 130) IU/l
88 (5 – 45) IU/l
15 (35 – 50) g/l 
0.05 (0 – 5) ng/ml
Microbiology
Blood microscopy and bacterial culture Negative
Urine microscopy and bacterial culture
Throat swab Polymerase chain reaction (PCR)
Atypical pneumonia screen for Chlamydia and Legionella
QuantiFERON-TB (interferon-gamma release assay (IGRA)) 
Alcohol and Acid Fast Bacilli (AAFB) microscopy and 
bacterial culture of urine
Alcohol and Acid Fast Bacilli (AAFB) microscopy and 
bacterial culture of blood x 4
Microscopy
Cerebrospinal fl uid Clear, colourless, no organisms, lymphocytes <1 cm. Normal 
protein. Viral screen negative Cytology & AAFB negative
Pathology 
Bone marrow biopsy Reactive cells, no evidence of haematological malignancy
Virology
Human Immunodefi ciency virus (HIV), Hepatitis B surface 
antigen (HBV sAg), Hepatitis C virus (HCV)
Negative
Immunology
Anti-nuclear antibodies (ANA); anti-neutrophil cytoplasmic 
antibody (ANCA); Rheumatoid factor
ANA Negative; p-ANCA Positive; MPO/PR3 negative; 
Rheumatoid factor 68 (range 0 -20) IU/ml
Radiology
Chest radiography Post radiotherapy chronic scarring in the left mid zone. New 
bi-basal peri-bronchial patchy consolidation.
Ultrasound abdomen No evidence of biliary obstruction or cholangitis. Incidental 
thick walled bladder.
Computed tomography (CT) of body Multifocal areas of consolidation, a right pleural effusion, 
bi-basal patchy changes suggestive of possible infection/
malignancy (Figure 1) 
Magnetic resonance (MR) cholangiopancreatography Normal appearance
MR imaging of head No source of infection and no evidence of intracranial 
metastases
Echocardiogram Intact anatomy and function, normal valve opening
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initially reluctant to attend hospital again so the hospital 
community team visited him at home and after two days he 
was persuaded to be re-admitted.
On admission his blood pressure was 135/90 mmHg, 
temperature 38.5oC, heart rate 79 beats per minute, and 
respiratory rate 20 breaths per minute, saturating 91% on 
air. Initial examination revealed him to be mildly inattentive, 
but orientated, with non-icteric sclerae and dry mucous 
membranes. There were no stigmata of endocarditis and no 
palpable lymph nodes. Auscultation revealed fi ne crepitations 
in the right lower zone, normal heart sounds and no signs 
of heart failure. His abdomen was soft and non-tender with 
no organomegaly. Bladder scan revealed a residual volume 
of 400ml. Peripheral and central neurology were normal and 
calves were soft and non-tender.
Blood tests revealed a pancytopenia with newly deranged 
liver biochemistry (Table 1). CT of the chest, abdomen 
and pelvis demonstrated dispersed multifocal areas of 
consolidation (Figure 1), and a right-sided pleural effusion 
too small to aspirate.
Fever persisted in spite of a 72-hour course of cefuroxime 
and metronidazole so that a comprehensive investigation 
for pyrexia of unknown origin was undertaken (Table 1). 
The patient had no history of tuberculosis (TB) otherwise. 
In the context of the investigations above and consultation 
with infectious disease specialists, empirical treatment for 
disseminated BCG was started on 26 October 2018.
Nine days after commencing rifampicin, isoniazid and 
ethambutol, fever resolved (Figure 2) and clinical improvement 
was evident. Having been bedbound, he was able again to 
sit out of bed and there were signs he had become more 
attentive. However, liver biochemistry deteriorated on 
treatment reaching a peak alanine aminotransferase (ALT) 
of 241 and bilirubin of 102 on day 12 of antituberculous 
therapy. On day 13, treatment was changed to ethambutol 
15mg/kg/day, levofl oxacin 500mg once a day and amikacin 
15mg/kg three times a week, whereupon liver biochemistry 
returned to normal so that the original choice of therapy 
could be re-instated. 
Thereafter the patient made a gradual recovery. After four weeks 
he was mobilising around the ward and his delirium resolved 
so that he could be discharged for further physiotherapy and 
support at home. It was planned that he would complete a 
nine-month course of antituberculous treatment.
Discussion
BCG vaccine is a live-attenuated vaccine derived from 
Mycobacterium bovis. Intravesical use of BCG immunotherapy 
was fi rst postulated in 1929 when it was noted that patients 
with TB demonstrated lower rates of cancer at autopsy.1 
Animal studies followed and in 1976 therapy was shown 
to be effective in nine individuals with recurrent superfi cial 
bladder cancer.2 For transitional cell carcinoma, BCG remains 
a highly effective therapy and BCG is currently listed as a 
fi rst-line treatment option for high-risk non-muscle-invasive 
bladder cancer in the United Kingdom.3 The mechanism of 
action remains incompletely understood but it is likely that 
the host immune response stimulated by BCG is deleterious 
to the cancerous cells.4 Anti-tumour effects appear greatest 
in patients who have a strong infl ammatory reaction to 
treatment.5
Reactions to BCG treatment can be categorised as local 
or systemic. Locally, irritative symptoms may represent 
granulomatous infl ammatory changes involving the structures 
of the genitourinary tract (e.g. cystitis, epididymitis or 
prostatitis). Systemic side effects range in severity from 
a fever and malaise, typically within the fi rst 48 hours of 
intravesical therapy, to disseminated granulomatous disease 
or BCG infection, which may be more insidious in onset 
but life threatening.6 Disseminated BCG affects less than 
Figure 1 Computerised Tomography (CT) cross-sectional image of 
the bases of both lungs demonstrating multifocal consolidation
Figure 2 Temperature chart for 
the duration of the admission
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1% of those treated,7 but its manifestations are protean, 
including single-organ infl ammatory disease (e.g. hepatitis, 
pneumonitis), subacute infection (e.g. mycotic aneurysm, 
osteomyelitis) or sepsis. Distinguishing hypersensitivity 
reactions to BCG from ongoing active BCG infection is diffi cult, 
and reactions may represent a combination of the two,8 there 
is evidence that both antimicrobial and corticosteroid therapy 
may be effective. 
Immunocompromise and mucosal damage have been 
implicated as potential risk factors for disseminated BCG 
disease.9 Our patient had a history of extensive pelvic 
radiation for the diagnosis of prostate cancer in 2016, 
recently started to self-catheterise, and was clinically 
suspected of having a urinary tract infection although the 
latter was never proven by microscopy or bacterial culture. 
Each of these three factors in our patient’s history may have 
contributed to signifi cant mucosal damage thereby providing a 
portal for BCG bacilli to enter the blood or lymphatic systems. 
The diagnostic yield from blood cultures is reported to be as 
low as 30%.6 Biopsies of non-caseating granuloma, where 
these are evident, can enable histological examination or 
culture with much higher diagnostic yields at 70%.6 Disease 
foci more amenable to biopsy include presentations where 
the prostate or bone is involved. However, biopsy is not 
helpful in cases presenting with widespread systemic disease 
as in our patient. In other reported cases, mycobacterial 
DNA has been successfully identifi ed in the bone marrow 
using deoxyribonucleic acid (DNA) hybridisation techniques10 
and in urine and liver specimens using polymerase chain 
reaction (PCR).11 In the majority of patients with disseminated 
BCG, the diagnosis relies chiefl y upon the exclusion of all 
reasonable alternatives, or following a positive response to 
antituberculous treatment.8
Conclusion
The case we present demonstrates that in patients presenting 
with pyrexia of unknown origin following BCG immunotherapy, 
particularly within the fi rst 24 hours of BCG instillation, 
clinicians should consider the possibility of disseminated 
BCG. If disseminated BCG is suspected, then treatment 
should not be delayed awaiting defi nitive microbiology as 
the diagnostic yield is low and consequences of the infection 
can be severe. 
Perhaps most saliently, this case reiterated the necessity, 
particularly in older people presenting with delirium, of a careful 
review of a patient’s medical records as well as discussing the 
history and clinical presentation with the family. 
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